Comparison of regadenoson (rapiscan) and central intravenous adenosine for measurement of fractional flow reserve

Comparison of regadenoson (rapiscan) and central intravenous adenosine for measurement of fractional flow reserve - Regadenoson and adenosine

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37223

Enrollment

100

Registered

2012-12-10

Start date

2013-01-03

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Induction of maximum coronary hyperemia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: See protocol.;Among others:;Age 18-80 years;Scheduled for invasive measurement of FFR

Exclusion criteria

Exclusion criteria: See protocol.;Among others:;Severe aortic valve stenosis;Severe COPD

Design outcomes

Primary

Measure	Time frame
Degree of coronary hyperemia and duration of hyperemic plateau phase.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results